Key facts
- Algen’s last known valuation is $24.0M (Feb 2022).
- It has raised $9.1M across 1 recorded rounds; the latest was Seed Round ($9.0M) in Feb 2022.
- Notable investors include Y Combinator, Viking Global Investors, Draper Associates, Endless Frontier Labs, Rebel Fund — 11 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Algen
Funding rounds
1 roundsAbout Algen
Developer of a medical platform designed to uncover disease-driving RNA messages. The company's technology utilizes CRISPR gene-modulation and machine learning to find drugs that modulate RNA messages, including technologies and science to dissect complex disease signaling and gene networks, enabling drug companies to decode functional gene networks for drug discovery to find treatments for cancer and diseases with high unmet needs.
- Industry
- Discovery Tools (Healthcare)
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2018
- Employees
- 14
- Website
- algenbio.com/
- Ownership
- Privately Held (backing)
Algen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Algen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Algen in its N-PORT filings yet. We sweep new filings monthly.